

## Supplementary Appendix

Effects of metformin on disease flares in patients with systemic lupus erythematosus:  
post-hoc analyses from two randomized trials

Fangfang Sun<sup>1</sup>, MD.; Shikai Geng<sup>1</sup>, Msc; Haiting Wang<sup>1</sup>, Msc; Huijing Wang<sup>1</sup>, Msc; Zhe Liu<sup>1</sup>, Msc; Xiaodong Wang<sup>1</sup>, MD.; Ting Li<sup>1</sup>, MD.; Weiguo Wan<sup>2</sup>, MD.; Liangjing Lu<sup>3</sup>, MD.; Xiangyu Teng<sup>4</sup>, MD.; Laurence Morel<sup>4</sup> PhD. & Shuang Ye<sup>1</sup> MD.

1. Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiaotong University School of Medicine, Shanghai, China.
2. Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China
3. Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
4. Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA.

Fangfang Sun & Shikai Geng contributed equally to this manuscript.

Corresponding authors:

Laurence Morel, PhD. E-mail: [morel@pathology.ufl.edu](mailto:morel@pathology.ufl.edu); or,

Shuang Ye, MD. E-mail: [ye\\_shuang2000@163.com](mailto:ye_shuang2000@163.com)

Figure S1. Trial protocol.




Table S1. Disease flares during the trials.

	Metformin (n = 99)	Placebo/Nil (n = 102)	<i>p</i>
<b>Flare</b>	21 (21.2%)	36 (35.3%)	0.027
<b>Major Flares</b>	12 (12.1%)	24 (23.5%)	0.035
Lupus nephritis	4	9	/
Serositis	0	3	/
Neuropsychiatric SLE	1	2	/
Refractory Arthritis	2	1	/
Refractory Rash	2	0	/
Thrombocytopenia (<60 x10 <sup>9</sup> /L)	1	3	/
Mesenteric Vasculitis	1	1	/
Myositis	1	0	/
Vasculitic Rash	0	2	/
General Condition	0	2	/
Hyperglobulinemia	0	1	/
<b>Mild-to-moderate</b>	9	12	0.54
Rash	1	4	/
Arthritis	2	3	/
General Condition	2	3	/
Oral Ulcer	1	0	/
Proteinuria	1	1	/
Thrombocytopenia (<60 x10 <sup>9</sup> /L)	1	1	/
Cytopenia	1	0	/